

LEGISLATIVE BUDGET BOARD
Austin, Texas

FISCAL NOTE, 86TH LEGISLATIVE REGULAR SESSION

May 22, 2019

TO: Honorable Dan Patrick, Lieutenant Governor, Senate

FROM: John McGeady, Assistant Director Sarah Keyton, Assistant Director
Legislative Budget Board

IN RE: **SB1564** by West (Relating to access to medication-assisted treatment for opioid use disorder under Medicaid.), **As Passed 2nd House**

| |
|--|
| <p>No significant fiscal implication to the State is anticipated.</p> |
|--|

The bill would require the Health and Human Services Commission (HHSC) to amend certain policies to authorize Medicaid reimbursement for the prescribing of buprenorphine for the treatment of an opioid use disorder by an advanced practice registered nurse meeting certain Texas Board of Nursing and federal requirements. With certain exceptions, HHSC would be required to provide medical assistance reimbursement for medication-assisted opioid or substance use disorder treatment without requiring preauthorization or precertification for the treatment.

HHSC estimates there would be a minimal cost associated with amending certain policies. It is assumed that related costs could be absorbed within existing agency resources.

This analysis assumes that any system modifications to the vendor drug claims processing system and other technology services at HHSC, as well as impacts to supplemental Medicaid drug rebate revenue can be absorbed within existing agency resources. HHSC indicates that requiring Medicaid reimbursement for medication-assisted opioid or substance use disorder treatment without requiring a prior authorization or pre-certification could result in a loss of supplemental Medicaid drug rebates.

Local Government Impact

No fiscal implication to units of local government is anticipated.

Source Agencies: 529 Health and Human Services Commission

LBB Staff: WP, AKi, LR, ADe